When a new drug enters the market, it generally causes a reawakening of issues that are understood but often not well appreciated. Such is the case of adding Pradaxa to warfarin as a drug available for the treatment of stroke prevention in atrial fibrillation.
One would think that after 60 years, we would have a better handle on the bleeding events that these drugs cause, but it seems that we get further and further from the mark. I have reviewed some of this information in the past, and I urge those of you who have not read about this topic before to check out those blogs.